Order byBest matchMost fresh

Hims, Zepbound and Sell Lilly

Digest more
Top News
Impacts
The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.
From The Wall Street Journal
Strong numbers here could set the stage for approval for orforglipron for a major indication.
From The Motley Fool

Read more on News Digest

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims to Sell Lilly’s Zepbound Through Telehealth Platform
Hims & Hers Health Inc.’s shares rose Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions made by compounding pharmacies.
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Eli Lilly says company has no affiliation with Hims & Hers
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be
Why Hims & Hers Health Stock Soared Tuesday
Hims & Hers revealed Tuesday that it will begin offering branded versions of Eli Lilly's tirzepatide -- the active ingredient in weight loss
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro,
Modern Healthcare16h
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance, some patients may pay as little as $25, according to a report published by The Wall Street Journal.
Noom To Streamline Access to Zepbound® Vials with Noom GLP-1 Companion Through Integration with LillyDirect® Pharmacy Provider
This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members whose doctors have prescribed FDA-approved medications. Since 2023, Noom has offered branded medications,
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.
Explore more
Feedback